TELA Bio is a medical technology company focused on providing soft-tissue reconstruction solutions that support clinical outcomes by focusing on the preservation and restoration of the patient's own anatomy. Co.'s first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), engages in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials. In addition, Co. has also designed an OviTex product specifically for use in laparoscopic and robotic-assisted hernia repair, which it markets as OviTex LPR. Co.'s second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, engages in plastic and reconstructive surgery. The TELA stock yearly return is shown above.
The yearly return on the TELA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TELA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|